The effects of olmesartan and alfacalcidol on renoprotection and klotho gene expression in 5/6 nephrectomized spontaneously hypertensive rats

Yonago Acta Medica

Volumn 54, Issue 3, 2011, Pages 49-58

  Fukui, Takeaki ^a   Munemura, Chishio ^a   Maeta, Satoko ^a   Ishida, Chihiro ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Chronic renal failure; Fibroblast growth factor 23; Klotho gene; Vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; CREATININE; FIBROBLAST GROWTH FACTOR; MESSENGER RNA; OLMESARTAN; POTASSIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; GENE; GENE EXPRESSION; KLOTHO GENE; MALE; NEPHRECTOMY; NONHUMAN; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

EID: 83455258120     PISSN: 05135710     EISSN: 13468049     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Aizawa H, Saito Y, Nakamura T, Inoue M, Imanari T, Ohyama Y, et al. Downregulation of the klotho gene in the kidney under sustained circulatory stress in rats. Biochem Biophys Res Commun 1998;249:865-871.
2. Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, et al. Natural inhibitor of transforming growth factor-beta against scarring in experimental kidney disease. Nature 1992;360:361-364.
3. de Zeeuw D, Agarwal M, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 2010;376:1543-1551.
4. Doi S, Zou Y, Togao O, Postor JV, John GB, Wang L, et al. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 2011;286:8655-8665.
5. Doorenbos CR, van den Born J, Navis G, de Borst MH. Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nat Rev Nephrol 2009;5:691-700.
6. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 2005;289:F8-F28.
7. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol 2004;24:503-510.
8. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Snah A, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodaialysis. N Engl J Med 2008;359:584-592.
9. Haruna Y, Kashihara N, Satoh M, Tomita N, Namikoshi T, Sasaki T, et al. Amelioration of progressive renal injury by genetic manipulation of klotho gene. Proc Natl Acad Sci U S A 2007;104:2331-2336.
10. Judd SE, Raiser SN, Kumari M, Tangpricha V. 1, 25-dihydroxyvitamin D3 reduces systolic blood pressure in hypertensive adults: A pilot feasibility study. J Steroid Biochem Mol Biol 2010;121:445-447.
11. Isakova T, Gutierrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int 2009;76:705-716.
12. Kanazawa M, Kohzuki M, Yoshida K, Kurosawa H, Minami N, Saito T, et al. Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist: beyond the renoprotective effects of ACE inhibitor monotherapy in a spontaneous hypertensive rat with renal ablation. Hypertens Res 2002;25:447-453.
13. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, et al. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001;280:1015-1020.
14. Komba H, Fukagawa M. FGF23: a key player in mineral and bone disorder in CKD. Nefrologia 2009;29: 392-396.
15. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997;30:1289-1294.
16. Kuro-o M. Klotho and aging. Biochim Biophys Acta 2009;1790:1049-1058.
17. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
18. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006;281:6120-6123.
19. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64: 2272-2279.
20. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002;110:229-238.
21. Maeta S, Munemura C, Fukui T, Ishida C, Murawaki Y. Combination therapy with olmesartan and temocapril amelioretes renal damage and upregulates the klotho gene in 5/6 nephrectomized spontaneously hypertensive rats. Yonago Acta Med 2009;52:27-36.
22. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, et al. In vivo klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002;39:838-843.
23. Nakanishi S, Kazama JJ, Nii-kono T, Omori K, Yamashita T, Fukumoto S, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-1178.
24. Porteri E, Rodella L, Rizzoni D, Rezzani R, Paiardi S, Sleiman I, et al. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Press 2005;14:184-192.
25. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;76:88-95.
26. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, et al. Circulating FGF-23 is regulated by 1alpha, 25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005;280:2543-2549.
27. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000;15:770-779.
28. Shiraishi N, Kitamura K, kohda Y, Narikiyo T, Adachi M, Miyoshi T, et al. Increased endothelin-1 expression in the kidney in hypercalcemic rats. Kidney Int 2003;63:845-852.
29. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitoriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008;19:1613-1619.
30. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115-1125.
31. Tsujikawa H, Kurotaki Y, Fujimori T, Fukada K, Nabeshima Y. Klotho, a gene related to a syndrome resembling human premature aging, functions in a negative regulatory circuit of vitamin D endocrine system. Mol Endocrinol 2003;17:2393-2403.
32. Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and metaanalysis. J Hypertens 2009;27:1948-1954.